Georgetown University Neurology Clinical Research (GUNCR)

Actively Enrolling Trials

(Current as of March 2025)

Click on the diagnoses below to see our actively enrolling trials

Click on the name of a trial to view the trial’s page on clinicaltrials.gov

ALS, Idiopathic Inflammatory Myopathy (IIM) & MSA

Target ALS Biomarker Study; Longitudinal Biofluids, Clinical Measures, and At Home Measures (TALSLB)
- Study Coordinator: Cassie Holmes (cassie.holmes@georgetown.edu)
ASSESS ALL ALS Study
- Study Coordinator: Cassie Holmes (cassie .holmes@georgetown.edu)
PREVENT ALL ALS Study
- Study Coordinator: Cassie Holmes (cassie.holmes@georgetown.edu)

(MOVR) neuroMuscular ObserVational Research data hub
- Study Coordinator: Gabby Law (gfl11@georgetown.edu)
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants with Active Idiopathic Inflammatory Myopathy (ALKIVIA)
- Study Coordinator: Arthur Zimmer (az642@georgetown.edu)
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic NOH in Participants with Multiple System Atrophy (CYPRESS)
- Study Coordinator: Michelle Umali (mfu8@georgetown.edu)
A Study to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy (MSA): A Safety and Efficacy Study (TOPAS-MSA)
- Study Coordinator: Luke Lovelace (ll928@georgetown.edu)

Multiple Sclerosis (MS)

Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
- Study Coordinator: Grace Inserra (gi90@georgetown.edu)

Study to Evaluate Efficacy of a Modified Regimen of Ublituximab (ENHANCE)
- Study Coordinator: Grace Inserra (gi90@georgetown.edu)

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)
- Study Coordinator: Aastha Bhatnagar (ab4004@georgetown.edu)
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)
- Study Coordinator: Aastha Bhatnagar (ab4004@georgetown.edu)

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Patients With Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (Meteoroid)
- Study Coordinator: Grace Inserra (gi90@georgetown.edu)
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD) (cosMOG)
- Study Coordinator: Daniel Bustamante (db1621@georgetown.edu)

Neuromyelitis Optica (NMO)

CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD)
- Study Coordinator: Daniel Bustamante (db1621@georgetown.edu)
Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies
- Study Coordinator: Grace Inserra (gi90@georgetown.edu)

Parkinson’s Disease (PD)

Product Surveillance Registry (PSR)
- Study Coordinator: David Pisfil (ddp39@georgetown.edu)
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson’s Disease
- Study Coordinator: Michelle Umali (mfu8@georgetown.edu)
A Study of AAV2-GDNF in Adults With Moderate Parkinson’s Disease (REGENERATE-PD) (REGENERATE-PD)
- Study Coordinator: Luke Lovelace (ll928@georgetown.edu)
Lu AF28996 in Participants With Parkinson’s Disease (PD)
- Study Coordinator: Luke Lovelace (ll928@georgetown.edu)

Stroke

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery (ASPIRE)
- Study Coordinator: Michelle Umali (mfu8@georgetown.edu)

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK)
- Study Coordinator: Micah Hamilton (mgh62@georgetown.edu)

Neurology Clinical Research Staff